Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivolumab slows the growth of some types of cancer or stops them from getting worse. To test the safety of the drug. Eligibility: People 12 and older who have Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders or EBV-positive non-Hodgkin lymphomas with no standard therapy Design: Participants will be screened with: Medical history Physical exam Blood and urine tests CAT scan of the chest, abdomen, and pelvis Tumor and bone marrow biopsies (sample taken) Magnetic resonance imaging scan of the brain Lumbar puncture (also known as spinal tap) Positron emission tomography/computed tomography scan with a radioactive tracer Every 2 weeks, participants will get Nivolumab by vein over about 1 hour. They will also have: Physical exam Blood and pregnancy tests Review of side effects and medications During the study, participants will repeat most of the screening tests. They may also have other biopsies. After stopping treatment, participants will have a visit every 3 months for 1 year. Then they will have a visit every 6 months for years 2-5, and then once a year. They will have a physical exam and blood tests. ...
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma potwierdzonego przez lekarza chłoniaka EBV-dodatniego lub inną chorobę rozrostową limfocytów EBV-dodatnią.
- •Choroba pacjenta nie ustąpiła po standardowym leczeniu lub nie można go zastosować.
- •Pacjent przeszedł ostatnie leczenie związane z chłoniakiem co najmniej 2 tygodnie temu.
- •Pacjent jest starszy niż 12 lat.
- •Pacjent waży co najmniej 40 kg (dotyczy osób poniżej 18 lat).
- •Stan ogólny pacjenta pozwala na udział w badaniu (nie jest zbyt osłabiony chorobą).
✗ Disqualifies
- •Pacjent jest młodszy niż 12 lat.
- •Pacjent przeszedł przeszczep komórek macierzystych lub otrzymał kroplówkę z limfocytami dawcy mniej niż 100 dni temu.
- •Choroba pacjenta wymaga natychmiastowego leczenia standardowymi lekami.
- •Pacjent miał niedawno przeszczep narządu litego, po którym rozwinęła się choroba rozrostowa.
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
NCI Medical Oncology Referral Office
Christopher J Melani, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.